IP Library Granted Patent US 7,455,983
Granted Patent B2
US 7,455,983 · App. 10/949,181 · Granted Nov 25, 2008

Medium for growing human embryonic stem cells

Assignee: Geron Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,455,983
App. No.
10/949,181
Granted
Nov 25, 2008
Kind
B2
Abstract

This disclosure provides an improved system for culturing human pluripotent stem cells. Traditionally, pluripotent stem cells are cultured on a layer of mouse embryonic fibroblast feeder cells to prevent them from differentiating. In the system described here, the role of feeder cells is replaced by defined components added to the culture environment that support rapid proliferation without differentiation. The medium contains an isotonic buffer, a blend of essential nutrients such as protein and lipids, and an effective growth factor or combination of factors that promote proliferation while inhibiting differentiation. Culturing human embryonic stem cells in fresh medium on an extracellular matrix according to this invention causes the cells to expand surprisingly rapidly, while retaining the ability to differentiate into cells representing all three embryonic germ layers. This new culture system allows for bulk proliferation of pPS cells for commercial production of important products for use in drug screening and human therapy.

Claims (6)

1. A method of evaluating a media for culturing human embryonic stem (hES) cells in vitro to determine if they proliferate without differentiating, comprising culturing hES cells on an extracellular matrix and in a medium comprising:

an isotonic buffer;

a protein nutrient, comprising serum, serum replacement, albumin, or essential and non-essential amino acids;

lipids, fatty acids, or cholesterol, either as artificial additives or as the HDL or LDL extract of serum;

added fibroblast growth factor at a concentration of 40 ng/mL; and

added Flt-3 ligand at a concentration of 15 ng/ml; and culturing hES cells in the medium through at least four passages; and determining if the hES cells cultured in the medium have differentiated.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 11, 2013
From: GERON CORPORATION
To: ASTERIAS BIOTHERAPEUITCS, INC.
Reel/Frame 031578/0054 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2004
From: XU, CHUNHUI; LI, YAN; MANDALAM, RAMKUMAR
To: GERON CORPORATION
Reel/Frame 015907/0538 →
Continuity (11)
Continuation In Part 1023509400 · Sep 4, 2002
Continuation In Part 1094918100
Continuation In Part PCTUS010103000 · Jan 10, 2001
Provisional Application 6058784300 · Jul 13, 2004
Provisional Application 6031747800 · Sep 5, 2001
Provisional Application 6022006400 · Jul 21, 2000
Provisional Application 6021638700 · Jul 7, 2000
Provisional Application 6021373900 · Jun 22, 2000
Provisional Application 6021374000 · Jun 22, 2000
Provisional Application 6017558100 · Jan 11, 2000
Related Publication 20050037492A1 · Feb 17, 2005